VEGF as a mediator of tumor-associated immunodeficiency

Immunologic Research

Volumn 23, Issue 2-3, 2001, Pages 263-272

  Ohm, J E ^a   Carborne, D P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cellular Differentiation; Growth Factors; Transcription Factors; Tumor Immunity; VEGF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LYMPHOKINES; MODELS, IMMUNOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SELF TOLERANCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034984740     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:23:2-3:263     Document Type: Article

References (46)

1. Immunologic dysfunction in cancer
2. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis
3. Where have all the T cells gone? Mechanisms of immune evasion by tumors
4. Immunologic nonresponsiveness to tumors
5. Tumor-induced immunedysfunction
6. Tumor immunology
7. Escape from host-antitumor immunity
8. The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response
9. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
10. The Biology of Vascular Endothelial Growth Factor
11. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
12. Clinical significance of the determination of angiogenic factors
13. KDR receptor: A key marker defining hematopoietic stem cells
14. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
15. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
16. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors
17. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
18. Toward a genetic analysis of tumor rejection antigens
19. Human tumor antigens recognized by T lymphocytes
20. Tumor antigens recognized by T lymphocytes
21. Tumor Suppressor Gene-Derived Peptide Antigens
22. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
23. Identification of genes encoding T cell defined tumantigens
24. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis
25. IL1 and IL6 released by tumor-associated macrophages from human ovarian carcinoma
26. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses
27. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
28. Molecular and biological properties of the vascular endothelial growth factor family of proteins
29. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients
30. Angiogenesis and metastasis
31. Tnk1: A novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells
32. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoetic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
33. Myeloid progenitor cells regulatory effects of vascular endothelial cell growth factor
34. Clinical significance of defective dendritic cell differentiation in cancer
35. Nadaf S, Ohm JE, Carbone DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
36. New insights into the roles of ReL/ NF-kappa B transcription factors in immune function, hemopoiesis and human disease
37. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
38. The NF-kappa B/Rel and I kappa B gene families: Mediators of immune response and inflammation
39. Function and activation of NF-kappa B in the immune system
40. NF-κB Activation: The IκB Kinase Revealed
41. NF-κB: A Lesson in Family Values
42. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation
43. NF-kappa B: Ten years after
44. The NF-kappa B and I kappa B proteins: New discoveries and insights
45. Vascular endothelial growth factor (VEGF) and its receptors
46. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice